[Thromboembolic risk].
Campisi
M
M
Stacca
R
R
Tassi
A
A
Laganà
G
G
Piccinini
P
P
D000368:Aged; D004087:Dihydroergotamine / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000209:etiology* / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control; D013924:Thrombophlebitis / Q000209:etiology / Q000517:prevention & control
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; D004087:Dihydroergotamine; C036901:defibrotide; D006493:Heparin
Rischio tromboembolico.